Superior anti-inflammatory effects of narrow-spectrum kinase inhibitors in airway smooth muscle cells from subjects with chronic obstructive pulmonary disease
To the Editor:
Corticosteroid-resistant airway inflammation is central for chronic obstructive pulmonary disease (COPD) progression. It is perpetuated by the production of corticosteroid-sensitive and corticosteroid-insensitive inflammatory cytokines in local cells including human airway smooth muscle cells (HASMCs) in response to inflammatory mediators such as TNF-a and to pathogen-associated molecular patterns such as LPS. [1] [2] [3] Cytokines are regulated by various protein kinases that have in part redundant functions. 4, 5 Narrow-spectrum protein kinase inhibitors (NSKIs) are novel anti-inflammatory agents targeting p38MAPK and Src (RV568) or p38MAPK, Src, and Syk (RV1088). 4, 5 To be superior to current and prospective COPD treatment options, NSKIs should (1) reduce the expression of corticosteroid-resistant cytokines such as CXCL8, (2) reduce the expression of corticosteroid-sensitive cytokines such as GM-CSF with equal or better efficacy than do corticosteroids such as fluticasone propionate (FP), which is frequently used in COPD therapy, 6 and (3) reduce the expression of inflammatory cytokines more efficiently than do single kinase inhibitors (SKIs), particularly pan-p38MAPK inhibitors such as BIRB796 that are in development for COPD. 4 We hypothesized that RV568 and RV1088 fulfill these criteria.
HASMCs were isolated from tumor-free tissue of patients undergoing lung resection for carcinoma. They were obtained from current smokers with COPD (COPD HASMCs) or from never-or ex-smokers without any other lung disease than lung cancer (non-COPD HASMCs). For details, refer to this article's Online Repository at www.jacionline.org. As measured by ELISA, TNF-a and LPS both induced CXCL8 in cultivated HASMCs. This was inhibited by FP in non-COPD HASMCs but not in COPD HASMCs (see Fig E1, A and B, in this article's Online Repository at www.jacionline.org), which, therefore, are cell culture models of corticosteroid insensitivity. IC 50 and E max values are presented in Table I . FP inhibited TNF-a-or LPS-induced GM-CSF almost completely in both non-COPD and COPD HASMCs (Fig E1, C and D; Table I ), which, therefore, are cell culture models of corticosteroid sensitivity.
Because of the limited availability of COPD HASMCs, we tested the effects of SKIs first in non-COPD HASMCs. BIRB796 partially inhibited TNF-a-induced GM-CSF. Dasatinib (Src family inhibitor), R343 (Syk/ZAP-70 family inhibitor), and the dasatinib/R343 combination did not show any significant inhibitory effects. The BIRB796/R343 combination was not more effective than BIRB796 alone. The BIRB796/dasatinib combination completely suppressed TNF-a-induced GM-CSF and was more effective than BIRB796 alone. The BIRB796/ dasatinib/R343 triple combination was equally effective as the BIRB796/dasatinib double combination (see Fig E2, A and B, in this article's Online Repository at www.jacionline.org). This suggests that p38MAPK and Src but not Syk have dominant roles in the regulation of TNF-a-induced GM-CSF. Accordingly, the NSKIs RV568 and RV1088 resembled the effects of the BIRB796/dasatinib double or the BIRB796/dasatinib/R343 triple combination and completely inhibited TNF-a-induced GM-CSF without significant differences. Both NSKIs were superior to any SKI in single treatments ( Fig E2, A and B) . We then investigated the concentration-dependent effects of NSKIs in COPD HASMCs (see Table E1 in this article's Online Repository at www.jacionline.org) and compared with BIRB796 and FP. RV568 and RV1088 both almost completely suppressed TNF-a-induced GM-CSF without differences. Both NSKIs were superior to BIRB796. Both NSKIs were almost equally effective as FP (Fig 1, A and B ; Table I ). These data demonstrate that NSKIs block cytokine production in a COPD primary cell culture model of corticosteroid sensitivity.
BIRB796 partially suppressed TNF-a-induced CXCL8 in non-COPD HASMCs. Dasatinib, R343, and the dasatinib/R343 combination did not show significant inhibitory effects. The BIRB796/R343 combination was not more effective than BIRB796 alone. The BIRB796/dasatinib combination inhibited TNF-a-induced CXCL8 more effectively than BIRB796 alone but not completely. The BIRB796/dasatinib/R343 triple combination was superior to any single and double treatment (see Fig E3, A and B, in this article's Online Repository at www.jacionline.org). This suggests dominant roles of all 3 kinase families, p38MAPK, Src, and Syk, in the regulation of TNF-a-induced CXCL8. The NSKI RV568 resembled the effects of the BIRB796/dasatinib combined treatment and partially suppressed TNF-a-induced CXCL8. RV1088 was superior to RV568 and was slightly more effective than the BIRB796/ dasatinib/R343 triple combination. Both NSKIs were superior to any SKI in single treatments ( Fig E3, A and B) . In COPD HASMCs, RV568 partially inhibited TNF-a-induced CXCL8 and was more effective than BIRB796 (Fig 1, C and D ; Table I ). RV1088 completely suppressed TNF-a-induced CXCL8 and was superior to RV568 and BIRB796. Both NSKIs were superior to FP, which showed a weak effect. These data demonstrate that NSKIs block cytokine production in a COPD primary cell culture model of corticosteroid insensitivity. Bonferroni test was used to analyze for differences across stimulations. B, D, F, and H, One-sample t tests were used to compare drug effects vs a hypothetical value of 0 (5 no drug effect on TNF-a-or LPS-induced GM-CSF or CXCL8). The percent inhibition data of 10 27 mol/L for each drug were individually compared with 0 and between drugs. DMSO, Dimethyl sulfoxide. *P < .05, **P < .01, ***P < .001 vs unstimulated controls (Fig 1, A, C , E, and G) vs 0 (Fig 1, B , D, F, and H) or between values as indicated. §P < .05, § §P < .01, § § §P < .001 vs stimulation with TNF-a or LPS alone.
All 3 SKIs, BIRB796, dasatinib, and R343, as well as the combinations BIRB796/dasatinib and dasatinib/R343 did not significantly inhibit LPS-induced CXCL8 in non-COPD HASMCs. In contrast, the BIRB796/R343 double combination and the BIRB796/dasatinib/R343 triple combination both showed strong inhibitory effects (see Fig E4, A and B, in this article's Online Repository at www.jacionline.org). This suggests dominant roles for p38MAPK and Syk but not for Src in the regulation of LPS-induced CXCL8. As the BIRB796/dasatinib combined treatment, the NSKI RV568 did not significantly inhibit LPS-induced CXCL8. In contrast, RV1088 potently suppressed CXCL8 in LPS-exposed HASMCs and was almost equally effective as the BIRB796/R343 double and the BIRB796/dasatinib/R343 triple combination. RV1088 was superior to any SKI in single treatments ( Fig E4, A and B) . In COPD HASMCs, RV1088 almost completely inhibited LPS-induced CXCL8. RV1088 was superior to RV568, to BIRB796, and to FP, all of which only showed weak inhibitory effects (Fig 1, E and F; Table I ).
Dasatinib and R343 in single treatments and the dasatinib/ R343 combination did not inhibit LPS-induced GM-CSF in non-COPD HASMCs. BIRB796 single treatment as well as the BIRB796/R343 and BIRB796/dasatinib combinations all partially suppressed LPS-induced GM-CSF, and BIRB796/ dasatinib was most effective. The BIRB796/dasatinib/R343 triple combination was superior to any double combination (see Fig E5, A and B, in this article's Online Repository at www.jacionline. org). This suggests that p38MAPK-, Src-, and Syk-family kinases are involved in the regulation of LPS-induced GM-CSF. RV568 and RV1088 were equally effective as the BIRB796/dasatinib double or BIRB796/dasatinib/R343 triple combination, respectively. RV1088 was superior to RV568 and to any single and double treatment ( Fig E5, A and B) . In COPD HASMCs, RV1088 completely inhibited LPS-induced GM-CSF. RV1088 was superior to RV568 and to BIRB796, both of which showed partial inhibitory effects (Fig 1, G and H; Table I ). RV1088 was by trend also superior to the strong effects of FP.
Data in the Online Repository (see Figs E6 and E7 in this article's Online Repository at www.jacionline.org) suggest (1) that differential sensitivities of CXCL8 and GM-CSF for NSKIs in different models depend on transcriptional regulation and (2) that NSKIs affect posttranscriptional CXCL8 regulation in the TNF-a but not in the LPS model.
Our data provide strong evidence for a utility of a new anti-inflammatory therapeutic strategy in COPD: NSKIs suppress corticosteroid-sensitive and corticosteroid-insensitive cytokine production in in vitro models of COPD and they are superior to sole p38MAPK inhibition and to SKIs that target Src and Syk. Targeting p38MAPK, Src, and Syk may be more effective than targeting only 2 of these 3 kinases (details are discussed in this article's Online Repository at www.jacionline.org). The limitation of this study is a lack of kinase-specific approaches using siRNA or knockout experiments. We cannot exclude off-target effects (ie, effects on targets other than p38MAPK, Src, and/or Syk) of RV1088 and RV568 in our models even though the effects of the SKI combinations largely matched those of the NSKIs. Thus, the mechanisms and the precise roles of the 3 kinase families in HASMC-associated steroid-insensitive airway inflammation require further investigation. In addition, further clinical studies are needed to evaluate the therapeutic utility of NSKIs in COPD.
Role of TWIK-related potassium channel-1 in chronic rhinosinusitis
To the Editor:
Chronic rhinosinusitis (CRS) is a heterogeneous mucosal inflammation involving paranasal sinuses and its pathogenesis remains unclear. It is believed that defects in the innate immune function of the sinonasal epithelium, including decreased barrier function, lead to the activation of adaptive immune responses, contributing to chronic inflammation. [1] [2] [3] Actually, a defective epithelial barrier was found in CRS along with a decreased expression of tight junctional proteins. 4 Mucosal inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic rhinosinusitis without nasal polyps (CRSsNP) is associated with the infiltration of various inflammatory cells, which is dependent
METHODS HASMC donors
HASMCs were obtained from patients with or without COPD undergoing lung resection for carcinoma. All HASMC donors did not have any kind of infection (bacterial, viral, or parasitic) 2 months preceding lung resection. COPD patient characteristics are described in Table E1 : none of the subjects with COPD used oral or inhaled corticosteroids or received immunosuppressive treatment, and none reported any other serious illness (with the exception of lung carcinoma) or histories of allergies or asthma. COPD was diagnosed according to the criteria recommended by the National Institutes of Health. Subjects with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages I-III) had a history of cough with sputum production and/or dyspnea on most of the days of the month for at least 3 months a year during more than 2 years before the study and airflow limitation in spirometry after bronchodilation (FEV 1 /forced vital capacity <70%) as defined by the GOLD initiative. For some experiments, HASMCs of nonsmokers (neversmokers or ex-smokers who have quit smoking for more than 2 years) without airway obstruction (normal lung function), without any other lung disease than lung cancer, and without any inflammatory disease were used (hereafter called non-COPD HASMCs). For data in Figs E6 and E7, HASMCs of a mixed population (nonsmokers, smokers with or without COPD) were used.
This study was approved by the ethics committees of the Universities of Cologne (02-004) and Bochum (4257-12), Germany, and all patients gave their written informed consent.
HASMC isolation, characterization, cultivation, and stimulation
HASMCs were dissected from lobar or main bronchus tissue obtained from patients undergoing lung resection for carcinoma of the lung as described previously.
E1,E2 For HASMC isolation, tumor-free tissue was used. Characterization and cultivation was performed as described previously.
E1,E2
For stimulation, HASMCs were seeded at equal density in 6-well plates. Before stimulation, subconfluent cell monolayers (;90% confluence) in 6-well cell culture plates were deprived of serum for 24 hours as described previously.
E1,E2 HASMC stimulation was done in serum-free and low-glucose (1 g/L) Dulbecco modified Eagle medium with supplements as described previously.
E1,E2 HASMCs at passages 2 to 7 were left untreated, stimulated with recombinant human TNF-a (20 ng/mL; R&D Systems, Minneapolis, Minn, cat# 210-TA) and LPS (1 mg/mL; Sigma-Aldrich, Munich, Germany, cat# L7770), and/or were preincubated with the NSKIs RV1088 or RV568 (RespiVert Ltd, London, UK), with BIRB796, dasatinib, R343, or FP (all RespiVert Ltd) for 2 hours before TNF-a or LPS stimulation. Stimulation was done for 2 hours (for RNA analysis) or 72 hours (for cytokine measurements in culture supernatants). The optimal conditions for the stimulation of HASMCs with TNF-a and LPS have been determined in previous studies.
E1-E3 Drugs were dissolved in dimethyl sulfoxide and diluted in PBS before addition to the culture medium. Equal dimethyl sulfoxide concentrations were added in controls. In some experiments, cells were postincubated with drugs after TNF-a or LPS stimulation and cytokines were measured after 48 hours of stimulation. Gene transcription was inhibited with actinomycin D (Sigma-Aldrich, cat# A9415) at 5 mg/mL. Cell viability was determined by trypan blue staining as described previously.
E1,E2 None of the drugs induced cell death in HASMCs under the conditions used.
RNA isolation, quantitative RT-PCR, and ELISA DNA-free total RNA was extracted from 90% subconfluent HASMCs with the chromatography-based RNeasy technique (QIAGEN GmbH, Hilden, Germany, cat# 74106). Quantitative RT-PCR was done as described previously. E2 Values for target genes under the different stimulation conditions were normalized to glyceraldehyde 3-phosphate dehydrogenase reference signals to correct for putative differences in RNA/cDNA load. Primer sequences for GM-CSF, CXCL8, and glyceraldehyde 3-phosphate dehydrogenase have been published previously.
E2
CXCL8 and GM-CSF concentrations in cell culture supernatants were measured via Duo set ELISAs (R&D Systems, Biomedica, Vienna, Austria) according to standard protocols.
E1,E2
Statistical analysis Data sets were tested for a Gaussian distribution by histogram analysis. Comparisons across more than 2 stimulations were done with 1-way repeatedmeasures ANOVA (Gaussian distribution) or Friedman test (non-Gaussian distribution) with 95% CIs. For separate comparisons of each stimulation, post hoc Bonferroni, Dunnet, or Dunn test was performed. Comparisons between 2 parameters were analyzed by paired, 2-tailed student t test or 1-sample t test (data sets had a Gaussian distribution). Concentration response curves were calculated by nonlinear (sigmoidal) regression with variable parameters but minimum bottom value set to 2100 (5 100% reduction). IC 50 (concentration with 50% inhibitory effect) and E max (extrapolated maximal possible effect) values were calculated from these concentration response curves. All calculations were done with GraphPad Prism version 5.01 (GraphPad Software Inc, La Jolla, Calif).
RESULTS

NSKIs suppress CXCL8 and GM-CSF mRNA transcription
To provide additional mechanistic insights, we investigated whether NSKIs might block CXCL8 and GM-CSF transcription in HASMCs of mixed donors. TNF-a and LPS both increased CXCL8 and GM-CSF mRNA levels, suggesting an induction of transcription ( Fig E6) . The inhibitory effects of NSKIs on cytokine transcription were in line with their effects on cytokine release: RV1088 and RV568 both reduced TNF-a-induced CXCL8 mRNA, and RV1088 was more effective than RV568 (Fig E6, A) . RV1088 but not RV568 reduced LPS-induced CXCL8 mRNA (Fig E6, B) . Both NSKIs reduced TNF-a-and LPS-induced GM-CSF mRNA. They were equally effective in the TNF-a model (Fig E6, C) but RV1088 was more effective than RV568 in the LPS model (Fig E6, D) . These data suggest that differential sensitivities of CXCL8 and GM-CSF for NSKIs in different models depend on transcriptional regulation.
NSKIs have posttranscriptional effects on CXCL8 in the TNF-a but not in the LPS model
We further investigated whether NSKIs might also have posttranscriptional effects in our models. General transcriptional activity was stopped by incubation of HASMCs of mixed donors with actinomycin D 6 hours after stimulation with TNF-a or LPS. We could not measure cytokine production after 72 hours of stimulation as we have done in the previous experiments because 66 hours of incubation with actinomycin D induced cell death in HASMCs of some donors (data not shown). Therefore, we reduced the time of stimulation to 48 hours when actinomycin D did not induce cell death in HASMCs of any donor (data not shown). Consistent with previous data, E2,E3 TNF-a and LPS induced statistically significant and robust CXCL8 but not GM-CSF release from HASMCs after 48 hours (Fig E7, data not  shown) . Therefore, we analyzed only CXCL8. NSKIs were added 30 minutes after actinomycin D and 6.5 hours after stimulation with TNF-a and LPS (postincubation). Postincubation with NSKIs in the absence of actinomycin D reflected the data obtained from preincubation experiments above, although both NSKIs were slightly less effective at postincubation versus preincubation: both NSKIs blocked TNF-a-induced CXCL8, and RV1088 was more effective than RV568 (Fig E7, A) , but only RV1088 blocked LPS-induced CXCL8 (Fig E7, B) . Actinomycin D blocked CXCL8 release in both models (Fig E7) . Additional treatment with NSKIs further reduced TNF-a-induced CXCL8, but, interestingly, without differences between RV1088 and RV568 (Fig E7, A) . In the LPS model, both NSKIs did not further reduce CXCL8 in the presence of actinomycin D (Fig E7, B) . This suggests that NSKIs affect posttranscriptional CXCL8 regulation in the TNF-a but not in the LPS model. Because the posttranscriptional effects of RV1088 and RV568 are equal, they do not contribute to the differential sensitivity of CXCL8 to the 2 NSKIs, and Syk may not be involved in posttranscriptional CXCL8 regulation.
DISCUSSION HASMCs as an in vitro model to test antiinflammatory drugs for COPD therapy
Airway smooth muscle (ASM) cells contribute to airway inflammation by responding to inflammatory mediators such as TNF-a with the production and release of cytokines.
E1 TNF-a levels are increased in stable COPD in any disease stage and are further increased in exacerbated disease. E4 This suggests that the ASM is exposed to abnormally high TNF-a levels in vivo in subjects with COPD, indicating the clinical relevance of cultured HASMCs exposed to TNF-a as an experimental model to investigate novel anti-inflammatory therapeutic strategies for stable COPD. Airway infection with gram-negative bacteria is a major cause of exacerbations. E5 When bacteria enter the lung tissue, the ASM is exposed to bacterial pathogen-associated molecular patterns (PAMPs), for example, in exacerbated disease. Therefore, stimulation of cultured HASMCs with LPS, the major PAMP in gram-negative bacteria, is a further in vitro model with clinical relevance. We measured CXCL8 and GM-CSF, 2 key cytokines in airway inflammation and inflammation-induced airway remodeling in COPD. E4 Importantly, cultured HASMCs mimic the corticosteroid insensitivity of airway inflammation in most COPD phenotypes: corticosteroids efficiently suppress CXCL8 production in response to TNF-a in HASMCs of never-smokers but fail to do so in HASMCs of subjects with COPD. E2 This feature makes cultured HASMCs a valuable in vitro model for testing alternative anti-inflammatory drugs for COPD therapy.
Rationale for NSKIs in anti-inflammatory therapy
Recent research has focused on nonreceptor protein kinases as druggable targets. Inflammatory processes such as cytokine production are regulated by a complex signaling network involving different protein kinase families. Thus, an inhibitor that blocks only a specific kinase family might be ineffective because of redundant functions of closely related kinases of other families. E6 Indeed, systemic administration of a p38MAPK inhibitor had short-term anti-inflammatory effects in rheumatoid arthritis, but these effects wore off over time, likely because other mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase had taken over the pathogenic proinflammatory functions of p38MAPK. E7,E8 Drugs targeting multiple kinase families might be more effective and prevent molecular escape. Many protein kinases that are involved in inflammation also have multiple functions in nonpathogenic physiologic processes. In consequence, targeting too many kinases increases the risk of side effects, as does systemic administration. NSKIs were designed to keep an optimal balance between targeting a sufficient number of proinflammatory kinases to avoid redundancy and the occurrence of side effects, particularly when administered by inhalation.
E9
NSKIs versus FP and SKIs
Here we showed that both NSKIs tested, RV1088 and RV568, had significant anti-inflammatory effects in COPD HASMCs exposed to TNF-a and to LPS. Because TNF-a is increased in the lungs of subjects with COPD in stable and exacerbated disease, these data suggest the utility of both NSKIs in any stage of disease. HASMCs are exposed to LPS in vivo in response to acute and chronic infections with gram-negative bacteria that can cause exacerbations. The evidence of anti-inflammatory effects of both NSKIs in LPS-exposed HASMCs provides the first indication for a utility of these drugs in disease stages where therapy is most important.
The comparison of NSKIs to corticosteroids in cultured cells of subjects with COPD provides a first indication of antiinflammatory potential in this corticosteroid-unresponsive disease. RV1088 was very effective in the 2 corticosteroid-insensitive and in the 2 corticosteroid-sensitive models: in all 4 models, the E max values for the inhibition of cytokine expression were at 100%; 100 nM RV1088 was almost equally effective as 100 nM fluticasone in the 2 corticosteroid-sensitive models. Therefore, our data provide first evidence that RV1088 can not only compete with corticosteroids in suppressing sensitive cytokines but can also suppress cytokines, the key factor CXCL8, that are insensitive to corticosteroids. RV568 was clearly effective in at least 1 of the 2 corticosteroid-insensitive models and was not significantly weaker than fluticasone in the 2 sensitive models. E max values were at about 49% suppression of TNF-a-induced and at about 26% suppression of LPS-induced CXCL8. In the corticosteroidsensitive models, E max values were at about 93% suppression of TNF-a-induced GM-CSF and at about 78% suppression of LPS-induced GM-CSF. This was equally or slightly less effective than 100 nM fluticasone in TNF-a-or LPS-activated HASMCs, respectively, and also provides the first evidence for a utility of RV568 as an alternative anti-inflammatory therapy in COPD. However, there is a trend for RV568 to be stronger in the TNF-a compared with the LPS models whereas RV1088 was almost equally effective. This indicates that both drugs might have utility in stable COPD but that RV1088-derived drugs might be superior to RV568 in exacerbations caused by gram-negative bacterial infections.
In contrast to the tested NSKIs, both SKIs, dasatinib and R343, did not significantly reduce cytokine production in any of the tested conditions. Although high concentrations of dasatinib showed a trend to suppress GM-CSF in TNF-a-and LPSactivated HASMCs, both NSKIs had clearly superior efficacy. The effects of NSKIs, dasatinib, and R343 were compared in HASMCs of subjects without COPD. Nonetheless, we did not find indications for differences in the effects of RV1088 and RV568 on CXCL8 and GM-CSF production between cells of subjects with and without COPD.
BIRB796 blocks corticosteroid-sensitive and corticosteroidinsensitive cytokine production in macrophages of the lungs of subjects with COPD, E10 and the p38MAPK inhibitor PH-797804 improved lung function of subjects with COPD in a small clinical trial likely due to anti-inflammatory effects. E6 Our experiments were done in HASMCs of subjects with COPD: RV1088 and RV568 both had higher E max values than BIRB796 in all 4 models that we tested. Moreover, IC 50 values were all in the nanomolar range and those of both NSKIs were lower than those of BIRB796 in TNF-a-activated HASMCs. In LPS-activated HASMCs, the IC 50 values of RV1088 or RV568 were slightly higher or equal to those of BIRB796. Notably, the effects of RV568 and BIRB796 were weaker and not statistically significant on CXCL8 in LPS-activated HASMCs. The overall superiority of both NSKIs to BIRB796 was confirmed in cells of subjects without COPD. In conclusion, our data provide strong evidence for NSKIs to have superior anti-inflammatory effects in COPD not only in comparison to corticosteroids but also to SKIs including p38MAPK inhibitors.
Our data showing that the combined inhibition of p38MAPK/ Src/Syk or p38MAPK/Syk, respectively, suppresses FPinsensitive CXCL8 production indicate that those 3 protein kinase families are central players in corticosteroidunresponsive airway inflammation in COPD. In support of this, both Src-and Syk-family members can activate phosphoinositide-3-kinases (PI3K), E11 and PI3Kd has been suggested as a key player in corticosteroid-unresponsive airway inflammation in COPD. E12,E13 Inhibition of the PI3K pathway by PI3Kd blockers or by the novel macrolide/fluoroketolide solithromycin reverses the corticosteroid insensitivity of CXCL8 production and airway inflammation in several in vitro and in vivo models of COPD. E12-E14 In conclusion, targeting the Syk/Src/PI3K cascade is an auspicious strategy for anti-inflammatory therapy in COPD because it might reduce inflammatory cytokine production and restore corticosteroid responsiveness. However, it cannot be excluded that the mechanisms of corticosteroid insensitivity vary in different COPD phenotypes and in other lung diseases with corticosteroid-unresponsive airway inflammation. In corticosteroid-unresponsive severe asthma, the p38MAPK isoforms a and g have dominant roles. E15,E16 However, the NSKIs that have been used here target p38MAPKa and g, Src, and-in the case of RV1088-additionally Syk and therefore might be optimized to treat corticosteroid-unresponsive airway inflammation in a broader spectrum of lung diseases and disease phenotypes.
FIG E1.
Fluticasone reduces GM-CSF but not CXCL8 release in TNF-a-and in LPS-activated COPD HASMCs. COPD (left panels, n 5 4) or non-COPD (right panels, n 5 5 never-smokers) HASMCs were preincubated with FP 2 hours before stimulation with TNF-a (20 ng/mL) or LPS (1 mg/mL) for 72 hours. CXCL8 and GM-CSF were measured in cell culture supernatants by ELISA. Data are presented as mean 6 SEM. One-way repeated-measures ANOVA (A-D, P < .001) and post hoc Bonferroni test: **P < .01, ***P < .001 vs unstimulated controls; §P < .05, § §P < .01, § § §P < .001 vs TNF-a or LPS stimulation. One-way repeated-measures ANOVA (A and B, P < .001) and post hoc Dunnett or Bonferroni test was used to analyze for differences across stimulations. BIRB, BIRB796; DAS, dasatinib. **P < .01, ***P < .001 vs unstimulated controls; §P < .05, § §P < .01, § § §P < .001 vs stimulation with TNF-a alone; #P < .05, ##P < .01, ###P < .001 between data as indicated.
FIG E3. Effects of NSKIs vs SKIs on TNF-a-induced CXCL8 in non-COPD
HASMCs. Non-COPD HASMCs (n 5 5) were preincubated with NSKIs, SKIs, or SKI combinations at indicated concentrations (triangles in A indicate decreasing drug concentrations: 10 27 , 10 28 , and 10 29 mol/L) 2 hours before stimulation with TNF-a (20 ng/mL) for 72 hours. CXCL8 was measured in cell culture supernatants by ELISA. Data are presented as mean 6 SEM. One-way repeated-measures ANOVA (A and B, P < .001) and post hoc Dunnett or Bonferroni test was used to analyze for differences across stimulations. BIRB, BIRB796; DAS, dasatinib. ***P < .001 vs unstimulated control; §P < .05, § §P < .01, § § §P < .001 vs stimulation with TNF-a alone; #P < .05, ##P < .01 between data as indicated.
FIG E4. Effects of NSKIs vs SKIs on LPS-induced CXCL8 in non-COPD
HASMCs. Non-COPD HASMCs (n 5 4) (A) or (n 5 5) (B) were preincubated with NSKIs, SKIs, or SKI combinations at indicated concentrations (triangles in Fig E4, A, indicate decreasing drug concentrations: 10 27 , 10 28 , and 10 29 mol/L) 2 hours before stimulation with LPS (1 mg/mL) for 72 hours.
CXCL8 was measured in cell culture supernatants by ELISA. Data are presented as mean 6 SEM. One-way repeated-measures ANOVA ( Fig E4, A and B, P < .001) and post hoc Dunnett or Bonferroni test was used to analyze for differences across stimulations. BIRB, BIRB796; DAS, dasatinib. ***P < .001 vs unstimulated control; § §P < .01, § § §P < .001 vs stimulation with LPS alone.
FIG E5. Effects of NSKIs vs. SKIs on LPS-induced GM-CSF in non-COPD
HASMCs. Non-COPD HASMCs (n 5 4) (A) or n 5 5 (B) were preincubated with NSKIs, SKIs, or SKI combinations at indicated concentrations (triangles in Fig E5, A, indicate decreasing drug concentrations: 10 27 , 10 28 , and 10 29 mol/L) 2 hours before stimulation with LPS (1 mg/mL) for 72 hours.
GM-CSF was measured in cell culture supernatants by ELISA. Data are presented as mean 6 SEM. One-way repeated-measures ANOVA (A and B, P < .001) and post hoc Dunnett or Bonferroni test was used to analyze for differences across stimulations. BIRB, BIRB796; DAS, dasatinib. ***P < .001 vs unstimulated control; §P < .05, § §P < .01, § § §P < .001 vs stimulation with LPS alone; #P < .05 between data as indicated.
FIG E7.
NSKIs have posttranscriptional effects on CXCL8 in TNF-a-but not in LPS-activated HASMCs. HASMCs were stimulated for 48 hours with TNFa (n 5 9) or LPS (n 5 7). After 6 hours of stimulation, actinomycin D was added at 5 mg/mL. After 6.5 hours of stimulation (30 minutes after actinomycin D), RV1088 or RV568 was added at 10 27 mol/L (postincubations). CXCL8 was measured in cell culture supernatants by ELISA. Data are presented as mean 6 SEM. One-way repeated-measures ANOVA (A and B, P < _ .01) and post hoc Bonferroni tests: *P < .05, **P < .01, ***P < .001 vs unstimulated control or between data as indicated. § §P < .01, § § §P < .001 vs stimulation with TNF-a or LPS alone. 
